Status:
RECRUITING
Efficacy and Safety of Kukoamine B Mesilate in Sepsis Patients
Lead Sponsor:
Tianjin Chasesun Pharmaceutical Co., LTD
Collaborating Sponsors:
Southwest Hospital, China
Conditions:
Sepsis
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
Brief Summary
Phase II study of Kukoamine B Mesilate in Sepsis Patients
Detailed Description
To Assess Efficacy,Safety,Pharmacokinetics of Kukoamine B Mesilate in Sepsis Patients
Eligibility Criteria
Inclusion
- (1) The age of ≥ 18 years of age and ≤ 85 years of age, gender is not limited;
- (2) Meeting the diagnostic criteria for sepsis 3.0, i.e. sequential organ failure score (SOFA) increased by ≥2 points from baseline for patients with confirmed or suspected infection;
- (3) Confirmed or suspected bacterial infection (Pulmonary, abdominal，urinary system or hematogenous infections);
- (4) Infection-related organ failure does not exceed 48 hours; organ failure is defined as circulation, (SOFA) ≥ 3 points in at least one organ or system of the respiratory, kidney, liver, coagulation and central nervous system;
- (5) Childbearing age within six months without child care plan and agreed to take effective measures during the study of contraception;
- (6) Patients or guardians signed informed consent.
Exclusion
- (1) Pregnancy or lactation women；
- (2) Patients are expected to live less than 48 hours;
- (3) Patients had poor control of malignant tumor, end-stage lung disease and other end-stage diseases, or had acardiac arrest，acute pulmonary embolism，blood transfusion response and acute coronary syndrome within 4 weeks prior to enrollment;
- (4) The patient has the following chronic organ dysfunction or immunosuppression (based on the chronic health scoring assessment of the APACHE II score) : 1) heart: New York heart association cardiac function IV; 2) breathing: chronic obstructive, obstructive, or vascular lung disease can lead to severe restrictions on activities, i.e. the inability to go upstairs or to do housework; Or clear chronic hypoxia, CO2 retention, secondary real erythrocyte, severe pulmonary hypertension (mPAP\> 40 mmHg) or respiratory muscle dependence; 3) kidneys: receiving long-term dialysis; 4) liver: liver cirrhosis confirmed by biopsy and clear portal hypertension; The upper digestive tract hemorrhage caused by portal hypertension; Or previous liver failure/hepatic encephalopathy/hepatic coma; 5) of immune function: accept the treatment of impact resistance to infection, such as immune suppression therapy, chemotherapy, radiotherapy or chemotherapy within 6 months, long-term (continuous use ≥3 weeks) use of glucocorticoids or recent (within 5 days before screening) cumulative use of prednisone or equivalent dose ≥100mg , or sickness impact resistance to infection, such as leukemia, lymphoma and AIDS);
- (5) Previous solid organ or bone marrow transplantation;
- (6) Plant survival status;
- (7) Confirmed or highly suspected of acute infectious diseases such as viral hepatitis activity , or clinically confirmed active tuberculosis;
- (8) Patients with sinus bradycardia (less than 60 per minute);
- (9) Uncontrolled bleeding in the past 24 hours（Clinical judgment requires transfusion support）;
- (10) Large area burns or chemical burns (III degree burns area \> 30% BSA);
- (11) The average arterial pressure was \< 65 mmHg after adequate liquid resuscitation and vasoactive drug therapy;
- (12) Acute myeloid hematopoiesis was characterized by a lack of severe granulocytes (ANC \< 500 / mm3);
- (13) Allergic to the active ingredient or its auxiliary materials;
- (14) The medication patients are using may severely affect the metabolism of the drug;
- (15) Patients and (or) guardians have signed a Do Not Rescue (DNR), or decided to withdraw life support (withdraw) or restrict life support for the intensity (withhold) and sign the informed consent form;
- (16) Participated in clinical intervention test in 3 months;
- (17) The subject is a researcher or his immediate family member, or may have improper informed consent;
- (18) The investigator considers it inappropriate for the patient to participate in this test.
Key Trial Info
Start Date :
May 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2024
Estimated Enrollment :
424 Patients enrolled
Trial Details
Trial ID
NCT04803955
Start Date
May 15 2021
End Date
June 30 2024
Last Update
April 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730